Novel protein transduction method by using 11R: An effective new drug delivery system for the treatment of cerebrovascular diseases

Stroke

Volumn 38, Issue 4, 2007, Pages 1354-1361

  Ogawa, Tomoyuki ^a   Ono, Shigeki ^a   Ichikawa, Tomotsugu ^a   Arimitsu, Seiji ^a   Onoda, Keisuke ^a   Tokunaga, Koji ^a   Sugiu, Kenji ^a   Tomizawa, Kazuhito ^a   Matsui, Hideki ^a   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cerebral vasospasm; Cerebrovascular disease protein; Enhanced green fluorescence protein; Transduction domain

Indexed keywords

ARGININE; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASILAR ARTERY; CEREBROVASCULAR DISEASE; CISTERNA MAGNA; CONTROLLED STUDY; DISEASE MODEL; DRUG DELIVERY SYSTEM; EX VIVO STUDY; FLUORESCENCE MICROSCOPE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; IN VIVO STUDY; INCUBATION TIME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBARACHNOID HEMORRHAGE; TUNICA MEDIA; ANIMAL; CHEMISTRY; DRUG EFFECT; FLUORESCENCE MICROSCOPY; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT; SPRAGUE DAWLEY RAT; SUBARACHNOID SPACE;

ANIMALS; ARGININE; BASILAR ARTERY; DRUG DELIVERY SYSTEMS; GREEN FLUORESCENT PROTEINS; MALE; MICROSCOPY, FLUORESCENCE; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; SUBARACHNOID SPACE;

EID: 34247857671     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000259887.70358.e0     Document Type: Article

References (35)

1. Khurana VG, Smith LA, Baker TA, Eguchi D, O'Brien T, Katusic ZS. Protective vasomotor effects of in vivo recombinant endothelial nitric oxide synthase gene expression in a canine model of cerebral vasospasm. Stroke. 2002;33:782-789.
2. Muhonen MG, Ooboshi H, Welsh MJ, Davidson BL, Heistad DD. Gene transfer to cerebral blood vessels after subarachnoid hemorrhage. Stroke. 1997;28:822-828.
3. Toyoda K, Faraci FM, Russo AF, Davidson BL, Heistad DD. Gene transfer of calcitonin gene-related peptide to cerebral arteries. Am J Physiol. 2000;278:H586-H594.
4. Onoue H, Tsutsui M, Smith L, Stelter A, O'Brien T, Katusic ZS. Expression and function of recombinant endothelial nitric oxide synthase gene in canine basilar artery after experimental subarachnoid hemorrhage. Stroke. 1998;29:1959-1966.
5. McGirt MJ, Parra A, Sheng H, Higuchi Y, Oury TD, Laskowitz DT, Pearlstein RD, Warner DS. Attenuation of cerebral vasospasm after subarachnoid hemorrhage in mice overexpressing extracellular superoxide dismutase. Stroke. 2002;33:2317-2323.
6. Watanabe Y, Chu Y, Andresen JJ, Nakane H, Faraci FM, Heistad DD. Gene transfer of extracellular superoxide dismutase reduces cerebral vasospasm after subarachnoid hemorrhage. Stroke. 2003;34:434-440.
7. Ono S, Komuro T, Macdonald RL. Heme oxygenase-1 gene therapy for prevention of vasospasm in rats. J Neurosurg. 2002;96:1094-1102.
8. Satoh M, Perkins E, Kimura H, Tang J, Chun Y, Heistad DD, Zhang JH. Posttreatment with adenovirus-mediated gene transfer of calcitonin gene-related peptide to reverse cerebral vasospasm in dogs. J Neurosurg. 2002;97:136-142.
9. Chen AFY, Jiang S-W, Crotty TB, Tsutsui M, Smith LA, O'Brien T, Katusic ZS. Effects of in vivo adventitial expression of recombinant endothelial nitric oxide synthase gene in cerebral arteries. Proc Natl Acad Sci U S A. 1997;94:12568-12573.
10. Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature (Lond). 1997;389:239-242.
11. Dorsch NW. Therapeutic approaches to vasospasm in subarachnoid hemorrhage. Curr Opin Crit Care. 2002;8:128-133.
12. Heistad DD, Faraci FM. Gene therapy for cerebral vascular disease. Stroke. 1996;27:1688-1693.
13. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997;15:647-652.
14. Templeton NS, Lasic DD. New directions in liposome gene delivery. Mol Biotechnol. 1999;11:175-180.
15. Ono S, Date I, Onoda K, Shiota T, Ohmoto T, Ninomiya Y, Asari S, Morishita R. Decoy administration of NF-kappaB into the subarachnoid space for cerebral angiopathy. Hum Gene Ther. 1998;9:1003-1011.
16. Jin LH, Bahn JH, Eum WS, Kwon HY, Jang SH, Han KH, Kang TC, Won MH, Kang JH, Cho SW, Park J, Choi SY. Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells. Free Radical. Biol Med. 2001;31:1509-1519.
17. Frankel A, Pabo C. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988;55:1189-1193.
18. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, and Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A. 1994;91:664-668.
19. Takenobu T, Tomizawa K, Matsushita M, Li ST, Moriwaki A, Lu YF, and Matsui H. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther. 2002;1:1043-1049.
20. Inoue M, Tomizawa K, Matsushita M, Yun-Fei Lu, Yokoyama T, Yanai H, Takashima A, Kumon H, Matsui H. p53 protein transduction therapy: successful targeting and inhibition of the growth of the bladder cancer cells. Eur Urol. 2006;49:161-168.
21. Wu HY, Tomizawa K, Matsushita M, Lu YF, Li ST, Matsui H. Polyarginine-fused calpastatin peptide, a living cell membrane-permeable and specific inhibitor for calpain. Neurosci Res. 2003;47:131-135.
22. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285:1569-1572.
23. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 1988;55:1179-1188.
24. Gustafsson AB, Sayen MR, Williams SD, Crow MT, Gottlieb RA. TAT protein transduction into isolated perfused hearts. Circulation. 2002;106:735-739.
25. Asoh S, Ohsawa I, Mori T, Katsura K, Hiraide T, Katayama Y, Kimura M, Ozaki D, Yamagata K, Ohta S. Protection against ischemic brain injury by protein therapeutics. PNAS. 2002;99:17107-17112.
26. Matsushita M, Tomizawa K, Moriwaki A, Li ST, Terada H, Matsui H. A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J Neurosci. 2001;21:6000-6007.
27. Matsushita M, Noguchi H, Lu YF, Tomizawa K, Michiue H, Li ST, Hirose K, Bonner-Weir S, Matsui H. Photo-acceleration of protein release from endosome in the protein transduction system. FEBS Lett. 2004;572:221-226.
28. Matsui H, Tomizawa K, Lu YF, and Matsushita M. Protein Therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery. Curr Protein Pept Sci. 2003;4(2):151-157.
29. Wadia JS, Stan RV Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med. 2004;10:310-315.
30. Ülkan K, Ertugrul K, Gunnar PHD, Mathias B. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke. 2003;34:1304-1310.
31. Michiue H, Tomizawa K, Wei FY, Matsushita M, Lu YF, Ichikawa T, Tamiya T, Date I, and Matsui H. The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. J Biol Chem. 2005;280:8285-8289.
32. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells? Trends in Cell Biol. 2000;10:290-295.
33. L is protective after middle cerebral artery occlusion in mice. Ann Neurol. 2002;52:617-622.
34. Yamaguchi M, Zhou C-M, Heistad DD, Watanabe Y, Zhang JH. Gene Transfer of extracellular superoxide dismutase failed to prevent cerebral vasospasm after experimental subarachnoid hemorrhage. Stroke. 2004;35:2512-2517.
35. Khurana VG, Meyer FB. Translational paradigms in cerebrovascular gene transfer. J Cerebral Blood Flow Metab. 2003;23:1251-1262.